Amplification and Selection of Antimicrobial Resistance in the Intestine II (ASARI II)

University Hospital Tuebingen

Status: Completed

Conditions: Antibiotic Selection Pressure

Treatments: Drug: meropenem

Study type: Observational

Funder types: Other

Identifiers

NCT03140826

ASARI-II

Details and patient eligibility

About

Stool samples will be collected from two groups of neutropenic patients in the case that a therapy with either meropenem or piperacillin/tazobactam is needed due to a suspected infection. The intestinal resistome will be determined and quantified using shotgun metagenomics. Based on this, regression models will be used to determine the actual selection pressure caused by these drugs, and both selective forces will be compared. The results will reveal if there is a drug that causes a lower selection pressure compared to the other. The study aims to generate knowledge that is required to design effective antibiotic stewardship programs.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hemato-oncological disease in neutropenia or with expected neutropenia
• Need for treatment with meropenem or piperacillin-tazobactam

Exclusion criteria

• pregnancy
• HIV, HBV, HCV

Trial design

60 participants in 2 patient groups

Meropenem arm

Description:

Patients receiving meropenem to treat an infection.

Treatment:

Drug: meropenem

Pip-Tazo arm

Description:

Patients receiving piperacillin-meropenem to treat an infection.